377 research outputs found
Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings
Restless legs syndrome (RLS) is one of the most common neurological disorders. It describes an irresistible urge to move the legs, mostly manifested in the evening and at night, which can lead to severe sleep disturbance. As part of the European Brain Council (EBC)-led Value-of-Treatment project, this study aimed at capturing the socioeconomic impact of RLS related to the inadequate diagnosis and treatment across different European healthcare settings. The economic burden of RLS was estimated using the published EBC framework of analysis in three separate European Union healthcare systems (France, Germany, and Italy). The RLS care pathway was mapped to identify the unmet needs of patients. Based on specific patient stories, the economic impact of correctly diagnosing RLS and changing between inadequate and target treatment was calculated using appropriate scenario analysis. RLS proved to be a significant personal and social burden, when epidemiological data, high prevalence of RLS, and its need for treatment are combined. By looking at the savings emerging from the provision of optimal care management (timely and correct diagnosis, evidence-based therapy, avoidance of therapy-related complications such as augmentation), the authors foresee substantial economic savings with the achievement of adequate diagnosis and treatment of RLS. Education about RLS is urgently needed for all subspecialties involved in RLS patient care as well as the general public. Equally important, the search for new causal treatment strategies should be intensified to reduce suffering and substantial societal cost
Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study
The European Restless Legs Syndrome (RLS) Study Group performed the first multi-center, long-term study systematically evaluating RLS augmentation under levodopa treatment. This prospective, open-label 6-month study was conducted in six European countries and included 65 patients (85% treatment naive) with idiopathic RLS. Levodopa was flexibly up-titrated to a maximum dose of 600Â mg/day. Presence of augmentation was diagnosed independently by two international experts using established criteria. In addition to the augmentation severity rating scale (ASRS), changes in RLS severity (International RLS severity rating scale (IRLS), clinical global impression (CGI)) were analyzed. Sixty patients provided evaluable data, 35 completed the trial and 25 dropped out. Augmentation occurred in 60% (36/60) of patients, causing 11.7% (7/60) to drop out. Median time to occurrence of augmentation was 71Â days. The mean maximum dose of levodopa was 311Â mg/day (SD: 105). Patients with augmentation compared to those without were significantly more likely to be on higher doses of levodopa (â„300Â mg, 83 vs. 54%, PÂ =Â 0.03) and to show less improvement of symptom severity (IRLS, PÂ =Â 0.039). Augmentation was common with levodopa, but could be tolerated by most patients during this 6-month trial. Patients should be followed over longer periods to determine if dropout rates increase with time
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations:Results of the open-label phase of the TOLEDO study
Introduction: The randomized, double-blind phase (DBP) of the TOLEDO study confirmed the efficacy of apomorphine infusion (APO) in reducing OFF time in PD patients with persistent motor fluctuations despite optimized oral/transdermal therapy. Here we report safety and efficacy results including the 52-week open-label phase (OLP). Methods: All patients completing the 12-week DBP (including those switching early to open-label treatment) were offered OLP entry. The primary objective was the evaluation of long-term safety of APO. Results: Eighty-four patients entered the OLP (40 previously on APO, 44 on placebo) and 59 patients (70.2%) completed the study. The safety profile of APO was consistent with experience from extensive clinical use. Common treatment-related adverse events (AEs) were mild or moderate infusion site nodules, somnolence and nausea. Fourteen (16.7%) patients discontinued the OLP due to AEs, those involving >1 patient were infusion site reactions (n = 4) and fatigue (n = 2); hemolytic anemia occurred in one case. Reduction in daily OFF time and improvement in ON time without troublesome dyskinesia were sustained for up to 64 weeks. Pooled data for week 64 (n = 55) showed a mean (SD) change from DBP baseline in daily OFF time of-3.66 (2.72) hours and in ON time without troublesome dyskinesia of 3.31 (3.12) hours. Mean (+/- SD) daily levodopa-equivalent dose decreased from DBP baseline to week 64 by 543 mg (+/- 674) and levodopa dose by 273 mg (+/- 515). Conclusions: The safety and efficacy of APO infusion were demonstrated with long-term use for persistent motor fluctuations, allowing substantial reductions in oral PD medication
Tau protein, A beta 42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies
The intra vitam diagnosis of dementia with Lewy bodies (DLB) is still based on clinical grounds. So far no technical investigations have been available to support this diagnosis. As for tau protein and beta-amyloid((1-42)) (Abeta42), promising results for the diagnosis of Alzheimer's disease ( AD) have been reported; we evaluated these markers and S-100B protein in cerebrospinal fluid (CSF), using a set of commercially available assays, of 71 patients with DLB, 67 patients with AD and 41 nondemented controls (NDC) for their differential diagnostic relevance. Patients with DLB showed significantly lower tau protein values compared to AD but with a high overlap of values. More prominent differences were observed in the comparison of DLB patients with all three clinical core features and AD patients. Abeta42 levels were decreased in the DLB and AD groups versus NDC, without significant subgroup differences. S-100B levels were not significantly different between the groups. Tau protein levels in CSF may contribute to the clinical distinction between DLB and AD, but the value of the markers is still limited especially due to mixed pathology. We conclude that more specific markers have to be established for the differentiation of these diseases. Copyright (C) 2005 S. Karger AG, Basel
Ultra-cold Polarized Fermi Gases
Recent experiments with ultra-cold atoms have demonstrated the possibility of
realizing experimentally fermionic superfluids with imbalanced spin
populations. We discuss how these developments have shed a new light on a half-
century old open problem in condensed matter physics, and raised new
interrogations of their own.Comment: 27 pages; 8 figures; Published in Report in Rep. Prog. Phys. 73
112401 (2010
King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation
Pain is a key unmet need and a major aspect of nonâmotor symptoms of Parkinson's disease (PD). No specific validated scales exist to identify and grade the various types of pain in PD. We report an international, crossâsectional, open, multicenter, oneâpointâinâtime evaluation with retest study of the first PDâspecific pain scale, the King's PD Pain Scale. Its seven domains include 14 items, each item scored by severity (0â3) multiplied by frequency (0â4), resulting in a subscore of 0 to 12, with a total possible score range from 0 to 168. One hundred seventyâeight PD patients with otherwise unexplained pain (age [meanâ±âSD], 64.38â±â11.38 y [range, 29â85]; 62.92% male; duration of disease, 5.40â±â4.93 y) and 83 nonspousal nonâPD controls, matched by age (64.25â±â11.10 y) and sex (61.45% males) were studied. No missing data were noted, and floor effect was observed in all domains. The difference between mean and median King's PD Pain Scale total score was less than 10% of the maximum observed value. Skewness was marginally high (1.48 for patients). Factor analysis showed four factors in the King's PD Pain Scale, explaining 57% of the variance (KaiserâMayerâOlkin, 0.73; sphericity test). Cronbach's alpha was 0.78, itemâtotal correlation mean value 0.40, and item homogeneity 0.22. Correlation coefficients of the King's PD Pain Scale domains and total score with other pain measures were high. Correlation with the Scale for Outcomes in PDâMotor, NonâMotor Symptoms Scale total score, and quality of life measures was high. The King's PD Pain Scale seems to be a reliable and valid scale for grade rating of various types of pain in PD. © 2015 International Parkinson and Movement Disorder Societ
Algorithms for the diagnosis and treatment of restless legs syndrome in primary care
<p>Abstract</p> <p>Background</p> <p>Restless legs syndrome (RLS) is a neurological disorder with a lifetime prevalence of 3-10%. in European studies. However, the diagnosis of RLS in primary care remains low and mistreatment is common.</p> <p>Methods</p> <p>The current article reports on the considerations of RLS diagnosis and management that were made during a European Restless Legs Syndrome Study Group (EURLSSG)-sponsored task force consisting of experts and primary care practioners. The task force sought to develop a better understanding of barriers to diagnosis in primary care practice and overcome these barriers with diagnostic and treatment algorithms.</p> <p>Results</p> <p>The barriers to diagnosis identified by the task force include the presentation of symptoms, the language used to describe them, the actual term "restless legs syndrome" and difficulties in the differential diagnosis of RLS.</p> <p>Conclusion</p> <p>The EURLSSG task force reached a consensus and agreed on the diagnostic and treatment algorithms published here.</p
First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire.
BACKGROUND AND PURPOSE: Pain is highly prevalent in Parkinson's disease (PD), impacting patients' ability, mood and quality of life. Detecting the presence of pain in its multiple modalities is necessary for adequate personalized management of PD. A 14-item, PD-specific, patient-based questionnaire (the King's Parkinson's Disease Pain Questionnaire, KPPQ) was designed corresponding to the rater-based KPP Scale (KPPS). The present multicentre study was aimed at testing the validity of this screening tool. METHODS: First, a comparison between the KPPQ scores of patients and matched controls was performed. Next, convergent validity, reproducibility (test-retest) and diagnostic performance of the questionnaire were analysed. RESULTS: Data from 300 patients and 150 controls are reported. PD patients declared significantly more pain symptoms than controls (3.96 ± 2.56 vs. 2.17 ± 1.39; P < 0.0001). The KPPQ convergent validity was high with KPPS total score (rS  = 0.80) but weak or moderate with other pain assessments. Test-retest reliability was satisfactory with kappa values â„0.65 except for item 5, Dyskinetic pains (Îș = 0.44), and the intraclass correlation coefficient (ICC) for the KPPQ total score was 0.98. After the scores of the KPPS were adapted for screening (0, no symptom; â„1, symptom present), a good agreement was found between the KPPQ and the KPPS (ICC = 0.88). A strong correlation (rS  = 0.80) between the two instruments was found. The diagnostic parameters of the KPPQ were very satisfactory as a whole, with a global accuracy of 78.3%-98.3%. CONCLUSIONS: These results suggest that the KPPQ is a useful, reliable and valid screening instrument for pain in PD to advance patient-related outcomes
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Background: The objective of this study
was to assess neurofilament light chain as a Parkinsonâs
disease biomarker.
Methods: We quantified neurofilament light chain in
2 independent cohorts: (1) longitudinal cerebrospinal fluid
samples from the longitudinal de novo Parkinsonâs disease cohort and (2) a large longitudinal cohort with serum
samples from Parkinsonâs disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, and mutation carriers.
Results: In the Parkinsonâs Progression Marker Initiative
cohort, mean baseline serum neurofilament light chain
was higher in Parkinsonâs disease patients (13 ïżœ 7.2
pg/mL) than in controls (12 ïżœ 6.7 pg/mL), P = 0.0336.
Serum neurofilament light chain increased longitudinally in
Parkinsonâs disease patients versus controls (P < 0.01).
Motor scores were positively associated with neurofilament light chain, whereas some cognitive scores
showed a negative association.
Conclusions: Neurofilament light chain in serum samples is increased in Parkinsonâs disease patients versus healthy controls, increases over time and with age,
and correlates with clinical measures of Parkinsonâs
disease severity. Although the specificity of neurofilament light chain for Parkinsonâs disease is low, it
is the first blood-based biomarker candidate that could
support disease stratification of Parkinsonâs disease
versus other cognate/neurodegenerative disorders,
track clinical progression, and possibly assess responsiveness to neuroprotective treatments. However, use of
neurofilament light chain as a biomarker of response
to neuroprotective interventions remains to be assessed
Metastability and Coherence of Repulsive Polarons in a Strongly Interacting Fermi Mixture
Ultracold Fermi gases with tuneable interactions represent a unique test bed
to explore the many-body physics of strongly interacting quantum systems. In
the past decade, experiments have investigated a wealth of intriguing
phenomena, and precise measurements of ground-state properties have provided
exquisite benchmarks for the development of elaborate theoretical descriptions.
Metastable states in Fermi gases with strong repulsive interactions represent
an exciting new frontier in the field. The realization of such systems
constitutes a major challenge since a strong repulsive interaction in an atomic
quantum gas implies the existence of a weakly bound molecular state, which
makes the system intrinsically unstable against decay. Here, we exploit
radio-frequency spectroscopy to measure the complete excitation spectrum of
fermionic 40K impurities resonantly interacting with a Fermi sea of 6Li atoms.
In particular, we show that a well-defined quasiparticle exists for strongly
repulsive interactions. For this "repulsive polaron" we measure its energy and
its lifetime against decay. We also probe its coherence properties by measuring
the quasiparticle residue. The results are well described by a theoretical
approach that takes into account the finite effective range of the interaction
in our system. We find that a non-zero range of the order of the interparticle
spacing results in a substantial lifetime increase. This major benefit for the
stability of the repulsive branch opens up new perspectives for investigating
novel phenomena in metastable, repulsively interacting fermion systems.Comment: 11 pages, 9 figure
- âŠ